# Carol A. Pollock

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/carol-a-pollock/

## Facts

| Field | Value |
| --- | --- |
| Citations | 28,316 |
| Field | Chronic Kidney Disease and Diabetes |
| h-index | 80 |
| i10-index | 313 |
| Last Known Institution | The University of Sydney |
| OpenAlex ID | https://openalex.org/A5016584401 |
| ORCID iD | https://orcid.org/0000-0001-7167-6495 |
| Works | 642 |

## Researcher papers

Showing 12 of 13.

- [Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy](https://scholariq.org/papers/canagliflozin-and-renal-outcomes-in-type-2-diabetes-and-nephropathy/)
- [Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy](https://scholariq.org/papers/global-kidney-health-2017-and-beyond-a-roadmap-for-closing-gaps-in-care-research/)
- [A Randomized, Controlled Trial of Early versus Late Initiation of Dialysis](https://scholariq.org/papers/a-randomized-controlled-trial-of-early-versus-late-initiation-of-dialysis/)
- [Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial](https://scholariq.org/papers/atrasentan-and-renal-events-in-patients-with-type-2-diabetes-and-chronic-kidney/)
- [Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference](https://scholariq.org/papers/iron-management-in-chronic-kidney-disease-conclusions-from-a-kidney-disease/)
- [Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference](https://scholariq.org/papers/dialysis-initiation-modality-choice-access-and-prescription-conclusions-from-a/)
- [Developing a Set of Core Outcomes for Trials in Hemodialysis: An International Delphi Survey](https://scholariq.org/papers/developing-a-set-of-core-outcomes-for-trials-in-hemodialysis-an-international/)
- [Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups](https://scholariq.org/papers/canagliflozin-and-cardiovascular-and-renal-outcomes-in-type-2-diabetes-mellitus/)
- [Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference](https://scholariq.org/papers/blood-pressure-and-volume-management-in-dialysis-conclusions-from-a-kidney/)
- [Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial](https://scholariq.org/papers/sparsentan-in-patients-with-iga-nephropathy-a-prespecified-interim-analysis-from/)
- [Establishing Core Outcome Domains in Hemodialysis: Report of the Standardized Outcomes in Nephrology–Hemodialysis (SONG-HD) Consensus Workshop](https://scholariq.org/papers/establishing-core-outcome-domains-in-hemodialysis-report-of-the-standardized/)
- [Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial](https://scholariq.org/papers/renal-cardiovascular-and-safety-outcomes-of-canagliflozin-by-baseline-kidney/)

## Researcher topics

- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Dialysis and Renal Disease Management](https://scholariq.org/topics/dialysis-and-renal-disease-management/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)

## Researcher university

- [The University of Sydney](https://scholariq.org/institutions/the-university-of-sydney/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.